Posted by on Aug 29, 2019 in news | 0 comments

BHI Therapeutic Sciences (BHITS) has been invited to present its abstract, “A retrospective chart review study of allogeneic umbilical cord blood mononuclear cell therapy for stroke,” at the German Stem Cell Network;s 7th Annual GSCN Conference being held Sept. 23-25 at the Max Delbruck Center for Molecular Medicine in Berlin. 

Marina Manvelyan, PhD., BHITS Clinical Research Scientist said: “We are excited to be part of this gathering to share knowledge with other scientists across the globe. We look forward to learning more about what our colleagues are focusing on in stem cell and regenerative therapies.”

The German Stem Cell Network (GSCN) aims to foster basic and applied stem cell research in Germany. The conference will cover the latest findings in stem cell biology in Germany and includes these scientific sessions:
• Pluripotency and reprograming
• Somatic stem cells and development
• Hematopoietic stem cells
• Stem cells in diseases: cancer stem cells
• Stem cells in regenerative therapies
• Stem cells in disease modeling and drug development
• Computational stem cell biology

“Stem cell therapies are, without a doubt, the future of medicine. I believe

they will become the preferred substitutes for many surgical,

pharmacological, and rehabilitative medical services,” 

“The importance of clinical trials and the key direction that it will take will truly

shape the way patients with chronic conditions, disorders, and acute diseases

are treated,” shared Brian Mehling, MD, Chief Medical Officer of BHITS.

BHITS abstract is focused on stroke. Stroke is a leading cause of adult disability worldwide and the second highest cause of death in the world. To date, there are no clinically effective pharmacotherapies that can promote or facilitate cellular functional recovery after an ischemic stroke. Human umbilical cord blood cell therapy is a promising treatment for ischemic stroke. The current retrospective chart review study is aimed to analyze the impact of human umbilical cord blood mononuclear cell therapy on mobility and muscle strength of upper and lower extremities, and neurological function in subjects with ischemic and hemorrhagic stroke.”

Ninety-seven subjects with ischemic and hemorrhagic stroke, treated with human umbilical cord blood mononuclear cells in the Wuhan Hongqiao Brain Hospital Co., Ltd. (Wuhan, Hubei) between March 2009 and March 2012, were included in the retrospective chart review study. Subjects received three administrations of 5 ml human umbilical cord blood mononuclear cells (3×10^8) isolated from human umbilical cord blood of three different donors. Treatment was conducted in three sessions via intravenous and intrathecal administrations. This retrospective chart review study was approved by an Institute of Regenerative and Cellular Medicine Institutional Review Board (IRCM approval number: IRCM-2017-135). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5).

Analysis of post-stroke physical conditions before and two months after the last human umbilical cord blood mononuclear cell therapy session showed improvement of upper and lower extremity mobility and muscle strength, and neurological function (ability to speak, urinary and bowel function). Significant improvement of upper and lower extremity muscle strength was observed in subjects with ischemic and hemorrhagic stroke, treated with human umbilical cord blood mononuclear cells in two or three intrathecal administrations.

 BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.   Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given us approval to proceed with our Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit

Leave a Reply

Your email address will not be published. Required fields are marked *